Sundin T
Scand J Haematol Suppl. 1977;32:222-7. doi: 10.1111/j.1600-0609.1977.tb01241.x.
Levels of iron and unsaturated iron binding capacity in serum and the renal excretion of iron were studied in 15 anaemic patients receiving Ferastral. Various dose schedules were used, 100 mg Fe daily for 10 days, 200 mg Fe daily for 5 days, and 500 mg Fe twice at various intervals from 2 to 7 days. A continuous increase of iron in serum was seen after the doses 100 mg and 200 mg daily as well as after 500 mg given at intervals of 2 and 3 days. Longer 500 mg dose intervals resulted in a fluctuation in the iron concentration. Peak levels varied between 740 and 5 260 microgram/100 ml (132 and 942 mumol/1). A transient decrease in the UIBC was seen. Urinary excretion of iron varied between 8.9 and 26.9% of the dose given. No local or general side effects occurred.
对15名接受Ferastral治疗的贫血患者的血清铁水平、不饱和铁结合能力以及铁的肾排泄情况进行了研究。采用了不同的给药方案,每日100毫克铁,共10天;每日200毫克铁,共5天;以及500毫克铁,在2至7天的不同间隔内分两次给药。每日100毫克和200毫克的剂量以及间隔2天和3天给予500毫克剂量后,血清铁持续升高。500毫克剂量间隔时间更长会导致铁浓度波动。峰值水平在740至5260微克/100毫升(132至942微摩尔/升)之间。不饱和铁结合能力出现短暂下降。铁的尿排泄量在给药剂量的8.9%至26.9%之间变化。未出现局部或全身副作用。